Results of the X-PECT study: A phase III randomized double-blind placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC).

被引：10
|
作者：
Bendell, Johanna C.
Ervin, Thomas J.
Senzer, Neil N.
Richards, Donald A.
Firdaus, Irfan
Lockhart, A. Craig
Cohn, Allen Lee
Saleh, Mansoor N.
Gardner, Lesa R.
Sportelli, Peter
Eng, Cathy
机构：
[1] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[2] Sarah Cannon Res Inst Florida Canc Specialists, Englewood, FL USA
[3] Mary Crowley Canc Res Ctr, Dallas, TX USA
[4] Texas Oncol Tyler, Tyler, TX USA
[5] Sarah Cannon Res Inst Oncol Hematol Care Inc, Cincinnati, OH USA
[6] Washington Univ, Sch Med, St Louis, MO USA
[7] Rocky Mt Canc Ctr LLP, Denver, CO USA
[8] Georgia Canc Specialists PC, Sandy Springs, GA USA
[9] Keryx Biopharmaceut Inc, New York, NY USA
[10] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
10.1200/jco.2012.30.18_suppl.lba3501
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA3501
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A randomized, double-blind, placebo-controlled, multicenter Phase II clinical trial of fruquintinib in patients with metastatic colorectal cancer (mCRC)
    Li, J.
    Xu, R.
    Bai, Y.
    Xu, J.
    Liu, T.
    Shen, L.
    Wang, L.
    Pan, H.
    Fan, S.
    Hua, Y.
    Su, W.
    Hugg, C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S366 - S366
  • [32] Initial efficacy evaluation of fruquintinib plus capecitabine versus capecitabine as maintenance treatment for metastatic colorectal cancer (mCRC): A randomized, controlled, phase Ib/II study.
    Li, Wenhua
    Chang, Jinjia
    Wang, Chenchen
    Peng, Junjie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 119 - 119
  • [33] Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)
    Hoff, Paulo M.
    Hochhaus, Andreas
    Pestalozzi, Bernhard C.
    Tebbutt, Niall C.
    Li, Jin
    Kim, Tae Won
    Koynov, Krassimir D.
    Kurteva, Galina
    Pinter, Tamas
    Cheng, Ying
    van Eyll, Brigitte
    Pike, Laura
    Fielding, Anitra
    Robertson, Jane D.
    Saunders, Mark P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (29) : 3596 - 3603
  • [34] A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (MAGNITUDE).
    Chi, Kim N.
    Rathkopf, Dana E.
    Attard, Gerhardt
    Smith, Matthew Raymond
    Efstathiou, Eleni
    Olmos, David
    Small, Eric Jay
    Lee, Ji Youl
    Ricci, Deborah S.
    Simon, Jason S.
    Zhao, Xin
    Kothari, Nishi
    Cheng, Shinta
    Sandhu, Shahneen Kaur
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel/Prednisolone in Patients with Hormone-Refractory Prostate Cancer
    Horti, Jozsef
    Widmark, Anders
    Stenzl, Arnulf
    Federico, Miriam H.
    Abratt, Raymond P.
    Sanders, Nick
    Pover, Gillian M.
    Bodrogi, Istvan
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2009, 24 (02) : 175 - 180
  • [36] Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer
    Eatock, M. M.
    Tebbutt, N. C.
    Bampton, C. L.
    Strickland, A. H.
    Valladares-Ayerbes, M.
    Swieboda-Sadlej, A.
    Van Cutsem, E.
    Nanayakkara, N.
    Sun, Y. -N.
    Zhong, Z. D.
    Bass, M. B.
    Adewoye, A. H.
    Bodoky, G.
    ANNALS OF ONCOLOGY, 2013, 24 (03) : 710 - 718
  • [37] Vandetanib plus mFOLFOX6 in patients with advanced colorectal cancer (CRC): A randomized, double-blind, placebo-controlled phase II study
    Yang, T. S.
    Oh, D. Y.
    Guimbaud, R.
    Szanto, J.
    Salek, T.
    Thurzo, L.
    Vieitez, J. M.
    Pover, G. M.
    Kim, T. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [38] AVAGAST: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE PHASE III STUDY OF CAPECITABINE/CISPLATIN + BEVACIZUMAB OR PLACEBO AS 1ST-LINE THERAPY IN PATIENTS WITH ADVANCED GASTRIC CANCER
    Ohtsu, A.
    Van Cutsem, E.
    Shah, M.
    Rha, S. Y.
    Sawaki, A.
    Park, S. R.
    Lim, H-Y
    Wu, J.
    Langer, B.
    Kang, Y-K
    ANNALS OF ONCOLOGY, 2010, 21 : 14 - 14
  • [39] Randomized phase II trial of capecitabine (X) versus X plus erlotinib (E) in patients (pts) with metastatic colorectal cancer (mCRC): Differential impact of KRAS.
    Vincent, M. D.
    Welch, S.
    Soulieres, D.
    Sanatani, M. S.
    Whiston, F.
    Stitt, L.
    O'Connell, A.
    MacKenzie, M. J.
    Kocha, W. I.
    Kerr, I. G.
    Dingle, B. H.
    Malpage, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF AMG 386 PLUS FOLFIRI IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC COLORECTAL CARCINOMA (MCC)
    Peeters, Marc
    Strickland, Andrew H.
    Lichinitser, Mikhail
    Suresh, Attili
    Manikhas, Georgy
    Shapiro, Jeremy
    Lakshmaiah, K. C.
    Rogowski, Wojciech
    Huang, Xin
    Wu, Benjamin
    Warner, Douglas
    Jain, Rajul
    Tebbutt, Niall
    ANNALS OF ONCOLOGY, 2011, 22 : v15 - v15
12345